A Multicenter Randomized Exploratory Clinical Trial to Evaluate the Effect of Bone Metabolism and the Efficacy of Evogliptin and Dapagliflozin for Blood Sugar in the Menopause Female Patients With Osteopenia and Type 2 Diabetes
试验速览
- 阶段
- 4 期
- 入组人数
- 120
- 试验地点
- 7
- 主要终点
- Change of bone density
研究概览
简要总结
This multi-center, randomized and exploratory clinical trial is designed to evaluate the effect of bone metabolism and blood sugar of evogliptin and dapagliflozin in the menopause female patients with osteopenia and type 2 diabetes.
The trial will evaluate bone metabolism (bone markers and bone density) and blood sugar (AGE and glucose variability) after 12 weeks and 48 weeks.
This clinical trial conducts in two arms, and each arm recruits 60 subjects.
详细描述
This clinical trial is to evaluate the effect of bone metabolism and blood sugar of evogliptin and dapagliflozin in the menopause female patients with osteopenia and type 2 diabetes.
Bone metabolism (bone markers and bone density) and blood sugar (AGE and glucose variability) after 12 weeks and 48 weeks will be evaluated.
This clinical trial conducts in two arms, and each arm recruits 60 subjects. If a subject voluntarily agrees to participate and meets the inclusion and exclusion criteria for the clinical trial, the subject will be randomly assigned to one of the two arms.
The total period after the subject enrollment is 48 weeks, and a total of six visits are made with screening, baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks.
Efficacy evaluation will be carried out changes on blood sugar, bone markers and density and after 12 and 48 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
盲法说明
The subject will be randomly assigned to one of the two arms. This is an open-label trial.
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women between 40 and 70 years of age with type 2 diabetes patients who are not taking diabetes drugs or who are not controlled by blood sugar at 7.0≤HbA1c≤9.0 while taking metformin
- •※ Menopause corresponds when one or more of the following three conditions are satisfied. (1) 12 months of amenorrhea (2) In the case of FSH≥40 mIL(milli-international unit)/mL in women over 50 years who have undergone a hysterectomy or 6 months of amenorrhea (3) Patients 6 weeks after ovariectomy
- •Lumbar, neck of femur and total femur bone density measurements were -2.4≤T-score≤-1.0
- •Obtained written informed consent from a patient
- •Patients who can participate during clinical trials and perform all planned trial procedures and visits.
排除标准
- •A person who has taken a diabetes medications other than metformin within 12 weeks, or who is hypersensitivity to DPP4(dipeptidyl peptidase-4) inhibitors or SGLT2 inhibitors.
- •AST(ASpartate Transaminase) or ALT(ALanine Transaminase) exceeds 2 times the upper limit of the normal range in laboratory tests
- •Patients with moderate or severe renal impairment, end-stage renal disease (ESRD) or dialysis
- •Patients whose eGFR(epidermal growth factor receptor) calculated using MDRD formula within 4 weeks before screening or at screening is less than 60 mL/minute/1.73 m2
- •In the case of osteoporosis medication dosage as follows:
- •Patients who have ever used bisphosphonate formulations
- •Patients who have used female hormones, SERM(Selective Estrogen Receptor Modulator), denosumab, and parathyroid hormone preparations within 12 months
- •Have bone or mineral metabolic diseases or have received treatment that affects them (1) Steroid; - Oral steroid 2.5mg or more has been continuously taken for more than 3 months from the date of consent - Continuous use of systemic or inhaled steroids for more than 3 months from the date of consent (2) Taking diuretics (3) Patients at risk for secondary osteoporosis
- •Patients who have participated in other clinical trials within 3 months
- •Patients with a history of malignant tumors within 5 years
- •Those who have a history of hypersensitivity to the main ingredients and additives of the trial drugs
- •Patients with type 1 diabetes or diabetic ketoacidosis
- •Patients with genetic problems such as galactose intolerance, Lapp deficiency, or glucose-galactose malabsorption
- •Any other patient that the investigator has determined is unsuitable for this clinical trial
研究组 & 干预措施
evogliptin
evogliptin 5 mg + metformin, oral administration once a day for 48 weeks
干预措施: Evogliptin (Drug)
dapagliflozin
dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
干预措施: Dapagliflozin (Drug)
结局指标
主要结局
Change of bone density
时间窗: Screening, 48 weeks
Change from screening bone density of lumbar spine 1-4, neck of femur and whole femur at 48 weeks
Change of 25OHD(25 Hydroxyvitamin D)
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone metabolism indicator 25OHD(25 Hydroxyvitamin D) at 12 weeks and 48 weeks
Change of CTX(C-terminal telopeptide of type I collagen)
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone marker CTX(C-terminal telopeptide of type I collagen) at 12 weeks and 48 weeks.
Change of 24 hour urine calcium
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone metabolism indicator 24 hour urine calcium at 12 weeks and 48 weeks
Change of P1NP(Procollagen type 1 Aminoterminal Propeptide)
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone marker P1NP(Procollagen type 1 Aminoterminal Propeptide) at 12 weeks and 48 weeks
Change of FGF23 (Fibroblast growth factor 23)
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone metabolism indicator FGF23(Fibroblast growth factor 23) at 12 weeks and 48 weeks
Change of PTH(Parathyroid Hormone) Intact
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone metabolism indicator PTH(Parathyroid Hormone) Intact at 12 weeks and 48 weeks
Change of 24 hour urine phosphate
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone metabolism indicator 24 hour urine phosphate at 12 weeks and 48 weeks
Change of 24 hour urine creatinine
时间窗: Baseline, 12 weeks, 48 weeks
Change from baseline bone metabolism indicator 24 hour urine creatinine at 12 weeks and 48 weeks
次要结局
- Change of HbA1C(Baseline, 12 weeks, 48 weeks)
- Change of FBS(Fasting Blood Sugar)(Baseline, 12 weeks, 48 weeks)
- Change of insulin(Baseline, 12 weeks, 48 weeks)
- Change of c-peptide(Baseline, 12 weeks, 48 weeks)
- Change of AGE(Advanced Glycation End Products)(Baseline, 12 weeks, 48 weeks)
- Change of CGM(Continuous Glucose Monitoring)(Baseline, 12 weeks, 48 weeks)
- Adverse events(12 weeks, 24 weeks, 36 weeks, 48 weeks)